Name of ResourceG51D SNCA rat (MRC Centre for Regenerative Medicine)
Name of Principal Investigator - Title
Name of Principal Investigator - First name
Name of Principal Investigator - Last name
Address of institution -InstitutionMRC Centre for Regenerative Medicine, Univerisity of Edinburgh
Address of institution - Street address
Address of institution - City
Address of institution - Postcode
SummaryCRISPR/Cas9 technology was used by Dr Tomoji Mashimo (Kyoto Univeristy) to introduce a single amino acid mutation (Gly-51-Asp) into the endogenous rat alpha-synuclein gene. This rat model is currently being characterised, but preliminary transcriptomic data on the midbrain of G51D/+ 11-month-old animal shows reduced expression of dopaminergic transcripts, including tyrosine hydroxylase. Frozen sperm for this model have been deposited into the National BioResource Project for the Rat in Japan ((http://www.anim.med.kyoto-u.ac.jp/NBR).
Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions? (1)Parkinson's disease & PD-related disorders
Q1b. Does your resource hold
Q2a. Does the resource act as a centre for access and distribution to external groups (who are not the Principal Investigators (PI) for the resource)?
Q2b. If Yes, what procedures and rules apply for access?Access independent of collaboration with PI| International access
Q3a. Does your resource develop experimental models (animal/cell) for external groups?
Q3b. If YES and your resource is related to an ANIMAL model, what types of models are provided?
Q3c. If YES and your resource is related to a CELL model, what types of models are provided?
Q4a. Is this activity supported as:
Q4b. Do you deposit what you supply in any kind of central repository?
Available to external user
Full phenotypic charactercharacterisation in-progress
Please indicate the phenotypesreduced tyrosine hydroxylase expression in midbrain of G51D/+ rats
List of genotypes or other subtypes
Q5b. Cognitive function, No of models
Q5b. Cognitive function, Available to external users
Q5b. Cognitive function, Full phenotypic characterisation
Q5b. Cognitive function, Nature of phenotype
Q5b. Motor function, No of models
Q5b. Motor function, Available to external users
Q5b. Motor function, Full phenotypic characterisation
Q5b. Motor function, Nature of phenotype
Q5b. Physiological function, no of models
Q5b. Physiological function, Available to external users
Q5b. Physiological function, Full phenotypic characterisation
Q5b. Physiological function, Nature of phenotype
Q5b. Other function (please specify), no of models
Please specify other function
Q5b. Other function (please specify), Available to external users
Q5b. Other function (please specify), Full phenotypic characterisation
Q5b. Other function (please specify), Nature of phenotype
Q6. Please indicate if your resource is already linked into European or international consortia or networks?National BioResource Project for the Rat in Japan
Q7a. Is maintenance of this resource dependent on continued funding?
Q7b. If yes, when does the current funding period end?
Q7c. What is the expected lifespan of the resource (in years)?
Q7d. Are there other plans affecting future use that it may be useful to know?
Types: Experimental Models
Member States: United Kingdom
Diseases: N/A
Years: 2016
Database Categories: N/A
Database Tags: N/A
Export as PDF